 TEL AVIV, Israel and NEW YORK, Jan. 06, 2022 GLOBE NEWSWIRE -- VBL Therapeutics Nasdaq: VBLT, a clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune-inflammatory indications, today announced that Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics, will present a corporate overview at the H.C. Wainwright BioConnect Virtual Conference being held on January 10 13, 2022. 